Current Document Type: HighlightsVideoPage New Findings on CLL, COVID-19, and Treatment With Obinutuzumab Plus Venetoclax - JADPRO

Watch More Highlights

Oxana Megherea, PharmD, BCOP, of Penn Medicine, University of Pennsylvania Health System, discusses results of a phase III study showing that progression-free survival with ibrutinib plus obinutuzumab plus venetoclax (IVO) is not superior to ibrutinib plus obinutuzumab (IO) for treatment-naive older patients with chronic lymphocytic leukemia in the setting of the COVID-19 pandemic. Long-term follow-up will determine whether there are advantages to IVO, with special attention to measurable residual disease and therapy discontinuation (Abstract 7500).

Copyright © 2010-2022 Harborside Press, LLC All rights reserved.               
Home | Current Issue | Previous Issue | Submissions | About JADPRO | Advertising | Privacy Policy | Contact | Copyright Notice/Disclaimer | Subscribe
Bot trap - Don't go here
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.